Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Murdoch Travis | CEO and President, Director | Buy (P) | 83K | $1.5M |
| Aug 7, 2026 | Lubner David Charles | Director | Buy (P) | 56K | $1000K |
| Aug 7, 2026 | Anderson Michele A. | Chief Development Officer | Buy (P) | 1K | $20K |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Buy (P) | 1.7M | $30.2M |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Buy (P) | 1.9M | $34.6M |
| Aug 7, 2026 | Rickey James Paul | Chief Financial Officer | Buy (P) | 28K | $500K |
| Aug 7, 2026 | Malek David I | Director | Buy (P) | 4K | $75K |
| Aug 7, 2026 | Viehbacher Christopher | Director | Buy (P) | 83K | $1.5M |
Connected entities for Braveheart Bio, Inc.
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/BRVE/capital-change-brief"
Use Arkolith's capital_change_brief for Braveheart Bio, Inc.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for BRVE. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.